Publications by authors named "Nabila Chaher"
Article Synopsis
- The study examined factors that influence treatment responses and survival outcomes in patients with inflammatory breast cancer (IBC) and locally advanced breast cancer (LABC).
- It involved analyzing tumor-infiltrating lymphocytes (TILs), CD20 B-cell frequencies, and PD-L1 expression levels in a cohort of 383 patients to assess their correlation with pathologic complete response (pCR) and survival rates.
- Results indicated that while several immune factors were associated with better outcomes, CD20PD-L1TILs specifically improved disease-free survival in IBC patients, suggesting potential for biomarker-guided therapy approaches.
Inflammatory breast cancer (IBC) in humans is the most aggressive form of mammary gland cancer and shares clinical, pathologic, and molecular patterns of disease with canine inflammatory mammary carcinoma (CIMC). Despite the use of multimodal therapeutic approaches, including targeted therapies, the prognosis for IBC/CIMC remains poor. The aim of this review is to critically analyze IBC and CIMC in terms of biology and clinical features.
View Article and Find Full Text PDFBackground: Inflammatory breast cancer (IBC) is a highly angiogenic disease; thus, antiangiogenic therapy should result in a clinical response. However, clinical trials have demonstrated only modest responses, and the reasons for these outcomes remain unknown. Therefore, the purpose of this retrospective study was to determine the prognostic value of protein levels of vascular endothelial growth factor (VEGF-A), one of the main targets of antiangiogenic therapy, and its receptors (VEGF-R1 and -R2) in IBC tumor specimens.
View Article and Find Full Text PDFArticle Synopsis
- High rates of inflammatory breast cancer (IBC) in Algeria are similar to those in Tunisia and Egypt, but specific epidemiological and molecular characteristics had not been previously studied in Algeria.
- In a comparison of 117 IBC cases to 59 non-IBC locally advanced breast cancers (LABC), it was found that IBC had lower rates of palpable masses and similar demographic and clinic-pathological traits, with most tumors classified as luminal A type.
- IBC showed worse overall survival compared to LABC, highlighting the need for improved therapeutic strategies as current treatments were found to be less effective in this population.
GPR30 is a novel G protein-coupled estrogen receptor (ER) associated with metastases in breast cancer (BC) and poor survival in endometrial and ovarian tumors. The association of GPR30 expression with inflammatory breast cancer (IBC), an aggressive and commonly hormone-independent form of BC, has not been studied. GPR30, ER, progesterone receptor (PR), epidermal growth factor receptor (EGFR), and HER-2 expression were assessed by immunohistochemistry (and FISH for HER-2) in 88 primary IBCs.
View Article and Find Full Text PDF